Mind Cure Health Begins Research Into Psychedelic Compounds

Mind Cure Health (CSE: MCUR) has reached a milestone, with the company this morning announcing its translational research program that will initially focus on the compounds of psilocybin, ibogaine, and ketamine. Research into the compounds is said to be largely focused on the treatment of physical and psychological pain and related mental health illnesses.

Translational research in layman terms is multidisciplinary and involves applying lab research and preclinical studies to developing clinical trials and studies in humans. Unlike applied science, translation research is said to be solely focused on improving health outcomes.

The program is intended to enable Mind Cure to investigate the compounds of psilocybin, ketamine and ibogaine for use in pharmaceuticals. All three are said to have demonstrated safety profiles that have a proven efficacy, but the compounds have yet to be optimized for medical use. The research will be focused on “delivering validation of commercially viable medicines, methods and tools to address numerous priorities in treating mental health.”

“Despite social stigmas, many classical psychedelics have safely demonstrated profound therapeutic effectiveness with alleviating all forms of pain associated with neurological trauma and chronic diseases. We begin our research with tremendous promise for new medicines that share structural similarities with improved receptor targeting, dosing, and therapeutic profiles.”

Dr. Ryan Hartwell

The company is currently focused on executing on this approach of research into psychedelics as a means of expediting research and development programs. Further, the program is said to holistically account for the lasting effects on quality of life and clinical outcomes in patients as a result of the mixed effects of physical and psychological pain.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Mind Cure Health last traded at $0.65 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Everybody Should Own Gold | George Bee – U.S. Gold Corp.

A $40M Company Created $2B in Mining Value | John-Mark Staude – Riverside Resources

The Debt Crisis Is Turning Gold Into Money | Shawn Khunkhun – Contango Silver and Gold

Recommended

Northmin Wins Competitive Bid for Historic Keel Zinc-Silver-Lead Deposit in Ireland

Brixton Hits 348 g/t Silver Over 23.5 Metres as Langis Shaft 6 Southeast Zone Extends South

Related News

Mind Cure Set To Launch Products Into Psychedelic Therapy Adaptogen Supplement Category

Mind Cure Health (CSE: MCUR) has completed the development of its first products. The company...

Tuesday, January 26, 2021, 08:43:59 AM

Mind Cure Health Appoints Rob Hill To Board Of Directors

Mind Cure Health (CSE: MCUR) this morning announced the appointment of Rob Hill to the...

Monday, February 22, 2021, 09:12:53 AM

Mind Cure Closes $3.6 Million Oversubscribed Financing

Mind Cure Health (CSE: MCUR) reported midday today that it has closed its non-brokered private...

Thursday, November 19, 2020, 04:28:12 PM

Mind Cure Appoints Dr Ryan Hartwell As Chief Science Officer

Mind Cure Health (CSE: MCUR) has a new executive. The company this morning announced that...

Tuesday, November 10, 2020, 08:57:19 AM

Mind Cure Doubles Bought Deal Financing To $20 Million

Strong demand continues within the psychedelics space, with Mind Cure Health (CSE: MCUR) announcing earlier...

Friday, January 22, 2021, 02:07:33 PM